Friday, October 10th, 2008 - Paper in Cell Cycle Reports Alfacell’s ONCONASE® Targets siRNA
Archive for the 'Onconase (ranpirnase)' Category
Thursday, May 29th, 2008 - Alfacell: Malignant mesothelioma treatment trial fails to meet primary endpoint
Wednesday, April 2nd, 2008 - Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
Friday, January 18th, 2008 - Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
Tuesday, January 15th, 2008 - Strativa Pharmaceuticals Acquires Commercialization Rights to Onconase(R) from Alfacell Corporation
Friday, June 8th, 2007 - Alfacell Announces Third-Quarter Financial Results and Highlights
Wednesday, April 18th, 2007 - ONCONASE® has Potential as Chemopreventive Agent in Mesothelioma, Reports World-Renowned Mesothelioma Researcher at AACR Annual Meeting
Monday, April 16th, 2007 - Preclinical Data Show Alfacell’s Onconase® Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells
Tuesday, January 30th, 2007 - Alfacell Corporation Granted U.S. Orphan Drug Designation for ONCONASE® for Treatment of Malignant Mesothelioma: First-in-Class RNAi Drug in Phase IIIB Confirmatory Trial for Unresectable
Thursday, December 21st, 2006 - Alfacell Corporation Files for U.S. Orphan Drug Designation for ONCONASE®
Wednesday, December 20th, 2006 - Alfacell Corporation and GENESIS Pharma S.A. Announce Exclusive Licensing Agreement for ONCONASE in Southeast Europe
Thursday, December 7th, 2006 - Alfacell Corporation Announces Company Succession Plan
Tuesday, October 24th, 2006 - Further Analysis of Phase III Data Using CALGB and EORTC Paradigms Reinforces Survival Benefits of ONCONASE® for the Treatment of Patients with Mesothelioma
Thursday, August 31st, 2006 - Alfacell Updates Progress on Clinical Development Program for ONCONASE® in Malignant Mesothelioma
